Skip to content
Subscribe Follow on LinkedIn
Press Releases profile photo

Press Releases

Would you like us to consider a press release for publication? Please email david@onyxnewsroom.com.

Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44

Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44

✨ Onyx Summary Avidity Biosciences reported new one-year data from the EXPLORE44 program showing that its exon 44–skipping therapy del-zota not only slowed but reversed disease progression in Duchenne muscular dystrophy patients, with improvements across multiple functional measures compared to natural history. Treatment led to sustained dystrophin production, normalization of

Avidity Biosciences Announces Proposed Public Offering of Common Stock

Avidity Biosciences Announces Proposed Public Offering of Common Stock

✨ Onyx Summary Avidity Biosciences (Nasdaq: RNA) announced plans to raise approximately $500 million through an underwritten public offering of its common stock, with an additional $75 million available to underwriters via a 30-day option. The company intends to use the proceeds to advance its three late-stage clinical programs, prepare for

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

✨ Onyx Summary Lexicon Pharmaceuticals submitted new clinical data to the FDA from three investigator-initiated studies supporting a potential resubmission of its New Drug Application for Zynquista® (sotagliflozin) as an adjunct to insulin therapy for adults with type 1 diabetes. The submission follows a 2024 FDA complete response letter citing safety

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

✨ Onyx Summary Keros Therapeutics presented additional Phase 1 data for KER-065 showing strong bone anabolic activity and increased bone mineral density in healthy volunteers, with the treatment well-tolerated across all dose levels. The results reinforce KER-065’s dual potential in Duchenne muscular dystrophy and bone disorders, supporting its continued clinical

ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

✨ Onyx Summary ImmunityBio reported Phase 2 data showing that ANKTIVA® (nogapendekin alfa inbakicept) can reverse therapy-induced lymphopenia in patients with checkpoint inhibitor–resistant advanced non-small cell lung cancer, with reversal linked to longer median overall survival (15.8 vs. 11.5 months; p=0.0057). The study suggests that restoring

Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States

Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States

✨ Onyx Summary Guardant Health announced a strategic partnership with PathGroup to expand access to its FDA-approved Shield™ blood test for colorectal cancer screening across 250+ hospitals, 15,000 physicians, and millions of patients in 25 states. By integrating Shield into PathGroup’s vast network and workflows, the collaboration represents a

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

✨ Onyx Summary Lexicon Pharmaceuticals will present preclinical data at NeuPSIG 2025 showing pilavapadin (AAK1 inhibitor) reduced neuropathic pain in models of chemotherapy-induced peripheral neuropathy and multiple sclerosis, with a separate poster on the Phase 2b PROGRESS study design. The update broadens pilavapadin’s potential beyond diabetic peripheral neuropathic pain, aligning

Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

✨ Onyx Summary Perspective Therapeutics has appointed Joel Sendek as Chief Financial Officer, effective immediately. Sendek, a veteran biotech finance executive with over $2.5 billion raised across prior CFO roles and a top-ranked equity research background, succeeds Juan Graham and is expected to strengthen the company’s financial and strategic

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

✨ Onyx Summary ✨ Onyx Summary enGene Holdings announced it has reached target enrollment of 100 patients in the pivotal cohort of its Phase 2 LEGEND trial evaluating detalimogene voraplasmid in high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The company plans to overenroll the cohort and now anticipates submitting a Biologics License Application

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

✨ Onyx Summary Perspective Therapeutics has appointed Maya Martinez-Davis, President of GSK’s U.S. Commercial business, to its Board of Directors as an independent director. Martinez-Davis brings over two decades of biopharma leadership across GSK, Merck KGaA, and Pfizer, strengthening the company’s strategic and commercial expertise as it advances